Kamada's ($KMDA) immunoglobulin treatment for rabies met its main goal in a late-stage trial, clearing the way for an FDA application next year. The therapy, dubbed KedRAB, is a one-time protein treatment designed to halt the rabies virus in patients who have already been exposed to it. In a Phase II/III trial, Kamada's injection met its primary endpoint of noninferiority with an older immunoglobulin therapy, and that top-line success should be enough to fuel an application for FDA approval by mid-2016, the company said. Release